secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001437749-25-017298
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree Q1 operating loss $4.1M, cash through May 2025; pivots to revenue via real estate
--------------------------------------------------------------------------------

- Operating loss $4.1M vs $4.4M prior year; net loss $5.0M ($4.63/share) vs net income $10.2M in Q1 2024.
- Cash and equivalents $1.2M at March 31, 2025; company believes funds operations only through May 2025.
- Closed private placement of Series D convertible preferred for $2.6M gross proceeds in April/May 2025.
- New strategy: secured right to buy a 436-unit multifamily property in Houston; signed supply agreement with Evofem for PHEXXI contraceptive gel.
- Istaroxime cardiogenic shock study enrolled; interim analysis of first 20 subjects expected in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774925017298/0001437749-25-017298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774925017298/wint20250206_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-017298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer